|
| Status |
Public on Oct 25, 2017 |
| Title |
Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Acute myeloid leukemia (AML) is an aggressive malignancy that can only be cured by intensive therapy. However, many elderly and unfit patients cannot receive such treatment due to an unacceptable risk of treatment-related morbidity and mortality. Disease-stabilizing therapy is then the only possible strategy, one alternative being treatment based on all-trans retinoic acid (ATRA) combined with the histone deacetylase inhibitor valproic acid and possibly low-toxicity conventional chemotherapy.
|
| |
|
| Overall design |
Primary AML cells were derived from patients included in two clinical studies of treatment based on ATRA plus valproic acid; low toxicity chemotherapy (low-dose cytarabine, hydroxyurea, 6-mercaptopurin) was also allowed. Pretreatment leukemic cells were analyzed by mutation profiling of 54 genes frequently mutated in myeloid malignancies and by global gene expression profiling before and during in vivo treatment.
|
| |
|
| Contributor(s) |
Reikvam H, Bruserud Ø |
| Citation(s) |
28877686, 33917201, 33946813 |
| Submission date |
Oct 24, 2017 |
| Last update date |
May 25, 2021 |
| Contact name |
Hakon Reikvam |
| E-mail(s) |
Hakon.Reikvam@uib.no
|
| Phone |
+4755585408
|
| Organization name |
University of Bergen
|
| Department |
Department of Clinical Science
|
| Street address |
Jonas Lies vei 65
|
| City |
Bergen |
| ZIP/Postal code |
5021 |
| Country |
Norway |
| |
|
| Platforms (1) |
| GPL10558 |
Illumina HumanHT-12 V4.0 expression beadchip |
|
| Samples (47)
|
|
| Relations |
| BioProject |
PRJNA415597 |
Less...
More...